Share on LinkedInShare on LinkedIn

ARTICLE · 01 MAY 2015

Claim Vitiation Does Not Foreclose The DOE

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

In Cadence Pharmaceuticals Inc. v. Exela PharmSci Inc., No. 14-1184 (Fed. Cir. Mar. 23, 2015), the Federal Circuit affirmed the district court’s claim construction, rulings of literal infringement...

United StatesIntellectual Property

In Cadence Pharmaceuticals Inc. v. Exela PharmSci Inc., No. 14-1184 (Fed. Cir. Mar. 23, 2015), the Federal Circuit affirmed the district court's claim construction, rulings of literal infringement and infringement under the DOE, and nonobviousness determination of the asserted claims.

SCR Pharmatop and Cadence Pharmaceuticals Inc. (collectively "Cadence") are the owner and exclusive licensee, respectively, of U.S. Patent Nos. 6,028,222 ("the '222 patent") and 6,992,218 ("the '218 patent"), which are directed to stable aqueous acetaminophen formulations.  Cadence markets an injectable acetaminophen product, which is approved by the FDA and is marketed under the name Ofirmev®.  The FDA's Approved Drug Products with Therapeutic Equivalence Evaluations ("Orange Book") lists the '222 and '218 patents as covering Ofirmev®.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from